2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: Design, synthesis, and SAR studies
作者:Caroline Meyers、Matilde Yáñez、Abdelaziz Elmaatougi、Tom Verhelst、Alberto Coelho、Nuria Fraiz、Guy L.F. Lemière、Xerardo Garcı´a-Mera、Reyes Laguna、Ernesto Cano、Bert U.W. Maes、Eddy Sotelo
DOI:10.1016/j.bmcl.2007.11.034
日期:2008.1
regioisomeric 2-substituted pyridazin-3(2H)-ones containing a 3-oxo-3-phenylprop-1-en-1-yl fragment at either position 4, 5 or 6 and 2-substituted pyridazin-3(2H)-ones containing the same fragment both at positions 4 and 5 have been synthesized and evaluated as antiplatelet agents. The study allows the identification of a new highly potent platelet aggregation inhibitor (4c).
一组区域异构的2-取代的哒嗪-3(2H)-在4、5或6位上含有3-氧代-3-苯基丙-1-烯-1-基片段和2-取代的哒嗪-3(2H) )-已经合成了在4和5位都含有相同片段的β-内酯,并将其评估为抗血小板剂。该研究可以鉴定出一种新型的高效血小板凝集抑制剂(4c)。